Logo of Neurizon Therapeutics (ASX:NUZ)Latest Neurizon Therapeutics (ASX:NUZ) News

Page 1
Page 1 of 6

Neurizon opens $2 million SPP with free options ahead of ALS trial results

Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
16 Nov 2026

Healthcare Wrap - Week 46 (9 Nov -> 13 Nov) 2026

EBR’s WiSE rollout slowed sharply as debt worries hit the stock, while Biome gained on a planned China launch.
Across aged care and healthcare technology, investors weighed stronger revenue against cash needs, trial delays and regulatory hurdles.
Logan Eniac
14 Nov 2026

Neurizon moves NUZ-001 ALS trial into active treatment extension

Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.
Ada Torres
13 Nov 2026

Market Wrap - Week 45 (2 Nov -> 6 Nov) 2026

NEXTDC, Vintage Energy and Embelton recorded the week’s biggest moves, but each came with a different reason and level of risk.
Across resources, takeovers and healthcare, investors rewarded firm deals while selling companies that still need cash or approvals.
Logan Eniac
7 Nov 2026

Healthcare Wrap - Week 45 (2 Nov -> 6 Nov) 2026

Healthcare shares delivered a mixed week as investors rewarded reimbursement and regulatory progress but punished cash calls and dilution. Noxopharm, Pacific Edge and Mayne Pharma led the largest moves, while several companies still face long waits before sales can grow.
Logan Eniac
7 Nov 2026

Neurizon clears convertible notes as $6.3m funding plan targets ALS trial readout

Neurizon says it has removed its remaining Obsidian convertible notes while targeting $6.3 million in new equity ahead of the pivotal NUZ-001 ALS readout. The funding plan reduces immediate conversion uncertainty, but the proposed Share Purchase Plan and possible future facility drawdown leave execution questions open.
Ada Torres
5 Nov 2026

Neurizon replaces convertible funding with A$6.3m equity raise ahead of ALS results

Neurizon Therapeutics has secured A$4.3 million through a discounted placement and is seeking another A$2.0 million from eligible shareholders, while redeeming its remaining Obsidian convertible notes. The move removes current note-conversion dilution, but shifts funding risk towards equity holders ahead of a pivotal NUZ-001 trial readout.
Ada Torres
2 Nov 2026

Market Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Exploration stocks dominated the biggest weekly moves, while several companies warned that cash, debt or approvals could decide what happens next.
Alvo Minerals led the market after heavy rare earth results, but company announcements remained a mixed source of confidence and concern.
Logan Eniac
10 Oct 2026

Healthcare Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Cynata led the week after launching a small capital raising, while Vitasora and Neurizon posted strong gains despite very different risks. Across healthcare, trial progress and regulator feedback competed with cash warnings and weaker share prices after trading gaps.
Logan Eniac
10 Oct 2026

FDA Opens Potential Single-Trial Approval Pathway for Neurizon’s NUZ-001

The FDA says positive results from Neurizon’s HEALEY ALS trial could potentially support traditional approval of NUZ-001, with the study possibly serving as the sole registrational trial. The guidance is conditional, but gives the company a clearer regulatory route ahead of topline results expected in late Q2 2027.
Ada Torres
6 Oct 2026

Market Wrap - Week 37 (7 Sept -> 11 Sept) 2026

Rare earths, scandium and biotech stocks led the week’s gains, while a rights issue sent Green & Gold Minerals sharply lower. Large capital raisings, mine funding and takeover activity kept resources at the centre of investor attention.
Logan Eniac
12 Sept 2026

Healthcare Wrap - Week 37 (7 Sept -> 11 Sept) 2026

Neurizon and Clever Culture Systems led the week with 35.71% gains, while CONNEQT also rose despite giving back part of its reopening move.
Biotech trial funding, device manufacturing and healthcare launches shaped investor decisions across the sector.
Logan Eniac
12 Sept 2026